[ad_1]
GOTHENBURG, SE / ACCESSWIRE / September 07, 2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, September 7, 2022 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, today announced that Richard Godfrey, CEO of IRLAB, will present at Pareto Securities’ 13th Annual Healthcare Conference in Stockholm, Sweden, on Thursday, September 8, 2022, at 11:00 am CEST.
A recording of the presentation will be made available on the company website, www.irlab.se, following the event.
For more information, please contact:
Richard Godfrey, CEO
Phone: +46 730 70 69 00
E-mail: [email protected]
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: [email protected]
About IRLAB
IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB’s strong clinical pipeline, the company is also progressing two preclinical programs, IRL942 and IRL757, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
Attachments
IRLAB to present at Pareto Securities’ 13th Annual Healthcare Conference
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/714954/IRLAB-to-Present-at-Pareto-Securities-13th-Annual-Healthcare-Conference
[ad_2]
Image and article originally from stocksnewsfeed.com. Read the original article here.